Member Info for draft

Could we see an after hours or tomorrow morning RNS

i wouldnt want to be out.... so Im not

10p please

Fact is theyve broken the rules, that shareholding should have been reported a long long time ago,

13% ??? and he only just tr1d??? maybe he wants to dump. ******

Very odd

Theres been no mini update yet

Any news on the Showcase/Light merger/takeover???

I just cant see any downside bad news here myself, unless ive totally missed something

Lol, u calling him a liar and same time your still here, odd person.

Has the same tone of a scam email tbh.

Current Activities and Outlook

During the period, ImmuPharma has made significant progress in advancing its lead asset, P140, while strengthening its strategic and financial position. The Company has continued to build scientific validation around P140's unique mechanism of action, reinforcing its potential as a differentiated treatment platform for autoimmune diseases.

A key priority has been progressing discussions with potential pharmaceutical partners. Engagement with multiple global organisations remains ongoing, although timelines for concluding a partnership have extended into 2026, reflecting the complexity and scale of such transactions.

AVION are still involved. there you go. Through this partnership, the CNRS will be entitled to receive from ImmuPharma low double-digit royalty payments of funds received by ImmuPharma from Avion through the Licence and Development Agreement and through further commercialisation deals for territories outside of the US.

Summary by AI BETAClose X

Immupharma PLC reported a loss for the twelve months ended 31 December 2025 of £1.8 million, an improvement from £2.5 million in 2024, with basic and diluted loss per share at 0.37p compared to 0.60p. The company's cash balance stood at £1.4 million at year-end, up from £0.2 million. Research and development expenses increased slightly to £1.3 million, while administrative expenses remained stable at £1.0 million. Post-period, Immupharma completed a £6.47 million fundraising in April 2026, comprising a £6 million subscription through Lanstead Capital and a £0.47 million retail offer. The company continues to advance its P140 autoimmune technology platform and its Kapiglucagon asset for metabolic disease.

Hey Wally

STFU

Fist of the North Star great film

Forget thermo fisher guys, forget that, its all about FDA

Clearly not done any research

Given stratton chuffed over his grand, well done

Nektan, i lost 10K, Bagir I lost 10K, theres a few where ive lost 10K . Dont go in too big, some of these shares are disasterous

Eh , id have to check my account for my buy in price

I could have 30 bagged that, such a moron for selling